CHEBI ONTOLOGY - ANNOTATIONS
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/ . The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/ ). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term: flumequine
Accession: CHEBI:85267
browse the term
Definition: A racemate comprising equimolar amounts of R- and S-flumequine. A broad-spectrum antibiotic, formerly used in veterinary medicine for stock breeding and treatment of aquacultures.
Synonyms: exact_synonym: rac-9-fluoro-5-methyl-1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-2-carboxylic acid
related_synonym: 9-Fluoro-6,7-dihydro-5-methyl-1-oxo-1H,5H-benzo(ij)quinolizine-2-carboxylic acid; flumequino; flumequinum
xref: CAS:42835-25-6; KEGG:D02302
xref_mesh: MESH:C012976
xref: PMID:23773949; PMID:24261869; PMID:24836135; PMID:25045079; PMID:25476307; PMID:25633214; Reaxys:490724; VSDB:1564; Wikipedia:Flumequine
G
Ccl2
C-C motif chemokine ligand 2
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CCL2 mRNA
CTD
PMID:23681119
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
G
Ccl3
C-C motif chemokine ligand 3
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CCL3 mRNA
CTD
PMID:23681119
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
G
Ccl4
C-C motif chemokine ligand 4
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CCL4 mRNA
CTD
PMID:23681119
NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231
G
Ccl7
C-C motif chemokine ligand 7
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CCL7 mRNA
CTD
PMID:23681119
NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303
G
Ccna2
cyclin A2
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CCNA2 mRNA
CTD
PMID:23681119
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
G
Ccnb1
cyclin B1
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CCNB1 mRNA; flumequine promotes the reaction [estragole results in increased expression of CCNB1 mRNA]
CTD
PMID:23681119 PMID:31029721
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
G
Ccnb2
cyclin B2
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CCNB2 mRNA
CTD
PMID:23681119
NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874
G
Ccnd1
cyclin D1
multiple interactions increases expression
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CCND1 mRNA flumequine results in increased expression of CCND1 mRNA
CTD
PMID:23681119
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
G
Ccne1
cyclin E1
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CCNE1 mRNA; [flumequine co-treated with estragole] results in increased expression of CCNE1 mRNA
CTD
PMID:23681119 PMID:31029721
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
G
Ccr2
C-C motif chemokine receptor 2
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CCR2 mRNA
CTD
PMID:23681119
NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100
G
Ccr7
C-C motif chemokine receptor 7
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CCR7 mRNA
CTD
PMID:23681119
NCBI chr10:84,098,193...84,108,309
Ensembl chr10:84,097,381...84,108,309
G
Cdk1
cyclin-dependent kinase 1
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CDK1 mRNA
CTD
PMID:23681119
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
G
Chek1
checkpoint kinase 1
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CHEK1 mRNA
CTD
PMID:23681119
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
G
Cyp1a1
cytochrome P450, family 1, subfamily a, polypeptide 1
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CYP1A1 mRNA
CTD
PMID:23681119
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
G
Cyp1a2
cytochrome P450, family 1, subfamily a, polypeptide 2
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CYP1A2 mRNA; [flumequine co-treated with estragole] results in increased expression of CYP1A2 mRNA
CTD
PMID:23681119 PMID:31029721
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
G
Cyp2b3
cytochrome P450, family 2, subfamily b, polypeptide 3
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CYP2B10 mRNA
CTD
PMID:23681119
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
G
Cyp7b1
cytochrome P450 family 7 subfamily B member 1
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in decreased expression of CYP7B1 mRNA
CTD
PMID:23681119
NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698
G
Exo1
exonuclease 1
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of EXO1 mRNA
CTD
PMID:23681119
NCBI chr13:87,809,725...87,834,654
Ensembl chr13:87,809,810...87,834,654
G
Fos
Fos proto-oncogene, AP-1 transcription factor subunit
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of FOS mRNA
CTD
PMID:23681119
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
G
Il1b
interleukin 1 beta
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of IL1B mRNA
CTD
PMID:23681119
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
G
Il36b
interleukin 36, beta
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in decreased expression of IL36B mRNA
CTD
PMID:23681119
NCBI chr 3:7,024,881...7,030,388
Ensembl chr 3:7,021,973...7,031,619
G
Jun
Jun proto-oncogene, AP-1 transcription factor subunit
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of JUN mRNA
CTD
PMID:23681119
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
G
Nfkb2
nuclear factor kappa B subunit 2
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of NFKB2 mRNA
CTD
PMID:23681119
NCBI chr 1:245,164,586...245,173,225
Ensembl chr 1:245,165,950...245,173,213
G
Rad18
RAD18 E3 ubiquitin protein ligase
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of RAD18 mRNA
CTD
PMID:23681119
NCBI chr 4:145,735,654...145,821,102
Ensembl chr 4:145,735,654...145,821,069
G
Rad51
RAD51 recombinase
multiple interactions
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of RAD51 mRNA
CTD
PMID:23681119
NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035
G
Tnf
tumor necrosis factor
multiple interactions increases expression
ISO
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of TNF mRNA; [flumequine co-treated with estragole] results in increased expression of TNF mRNA flumequine results in increased expression of TNF mRNA
CTD
PMID:23681119 PMID:31029721
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
G
Ugt1a1
UDP glucuronosyltransferase family 1 member A1
decreases expression multiple interactions
ISO
flumequine results in decreased expression of UGT1A1 mRNA [flumequine co-treated with estragole] results in decreased expression of UGT1A1 mRNA
CTD
PMID:23681119 PMID:31029721
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
G
Ugt2b1
UDP glucuronosyltransferase 2 family, polypeptide B1
decreases expression multiple interactions
ISO
flumequine results in decreased expression of UGT2B1 mRNA [flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in decreased expression of UGT2B1 mRNA
CTD
PMID:23681119
NCBI chr14:21,024,035...21,035,784
Ensembl chr14:21,024,006...21,035,986
Term paths to the root one shortest all shortest one longest all longest one shortest and longest all